Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

14.60
+0.16001.11%
Post-market: 14.600.00000.00%17:56 EDT
Volume:156.61K
Turnover:2.30M
Market Cap:378.24M
PE:-3.25
High:15.84
Open:14.19
Low:13.57
Close:14.44
Loading ...

Oppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)

TIPRANKS
·
Yesterday

Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress

TIPRANKS
·
17 Mar

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer

TipRanks
·
15 Mar

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
14 Mar

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger

TIPRANKS
·
14 Mar

Cartesian Therapeutics Advances mRNA Therapy Pipeline

TIPRANKS
·
14 Mar

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Dow Jones
·
14 Mar

Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position

TIPRANKS
·
14 Mar

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)

TIPRANKS
·
14 Mar

Cartesian Therapeutics FY 2024 GAAP EPS $(4.49) Beats $(4.98) Estimate, Sales $38.913M Miss $39.777M Estimate

Benzinga
·
13 Mar

Cartesian Therapeutics: Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis on Track to Commence in 1H25

THOMSON REUTERS
·
13 Mar

Cartesian Therapeutics : Phase 2 Trial of Descartes-08 in Systemic Lupus Erythematosus Ongoing With Expected Data Readout in 2H25

THOMSON REUTERS
·
13 Mar

Cartesian Therapeutics : Expects to Initiate Phase 2 Pediatric Basket Trial of Decartes-08 in Select Autoimmune Indications in 2H25

THOMSON REUTERS
·
13 Mar

Cartesian Therapeutics announces employment inducement grant

TIPRANKS
·
06 Mar

Cartesian Therapeutics Announces New Employment Inducement Grant

GlobeNewswire
·
06 Mar

Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Reuters
·
03 Mar